Core Viewpoint - Geely Automobile Holdings Ltd. has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][4][6]. Earnings Estimates and Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, with the Zacks Consensus Estimate reflecting EPS estimates from sell-side analysts [2][3]. - The recent upgrade for Geely Automobile suggests an improvement in its underlying business, which is expected to positively impact its stock price [4][6]. Impact of Earnings Estimate Revisions - Changes in future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements, particularly due to institutional investors' reliance on these estimates for valuation [5][7]. - For Geely Automobile, the Zacks Consensus Estimate for the fiscal year ending December 2025 is projected at $4.12 per share, unchanged from the previous year, but has seen a 7% increase in estimates over the past three months [9]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - Geely Automobile's upgrade to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10][11].

Investors might want to bet on Astrana Health, Inc. (ASTH) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a c ...

Core Viewpoint - Cadence (CADE) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often adjust their valuations based on earnings estimates, leading to significant stock price movements when they buy or sell large amounts of shares [4]. Cadence's Earnings Outlook - The upgrade for Cadence reflects an improvement in the company's underlying business, which is expected to drive the stock price higher as investors recognize this trend [5][10]. - For the fiscal year ending December 2025, Cadence is projected to earn $2.92 per share, with a 5.9% increase in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions and potential for market-beating returns [9][10].

Company Overview - Rhythm Pharmaceuticals, Inc. (RYTM) shares increased by 36.6% in the last trading session, closing at $89, with notable trading volume compared to typical sessions [1] - The stock had previously experienced a 3.3% loss over the past four weeks [1] Recent Developments - The stock's rally followed the announcement of positive top-line data from a phase II study of the investigational oral melanocortin-4 receptor (MC4R) agonist, bivamelagon, for patients with acquired hypothalamic obesity [2] - The study results indicated statistically significant and clinically meaningful reductions in body mass index after 14 weeks of treatment with bivamelagon [2] Financial Expectations - The company is projected to report a quarterly loss of $0.64 per share, reflecting a year-over-year change of -16.4% [3] - Expected revenues for the upcoming report are $43.76 million, which represents a 50.5% increase from the same quarter last year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating that stock price movements may not continue without trends in earnings estimate revisions [4] Industry Context - Rhythm Pharmaceuticals is part of the Zacks Medical - Biomedical and Genetics industry, which includes other companies like EyePoint Pharmaceuticals (EYPT) [5] - EYPT shares closed 10.2% higher at $10.96, with an 8% return over the past month [5] - EYPT's consensus EPS estimate for the upcoming report has also remained unchanged at -$0.67, representing a -15.5% change from the previous year [6]

Core Viewpoint - Red Robin (RRGB) has shown an 8.1% increase in stock price over the past four weeks, with a mean price target of $9.38 indicating a potential upside of 49.1% from the current price of $6.29 [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $3.94, where the lowest estimate is $3.50 (44.4% decline) and the highest is $12.00 (90.8% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about RRGB's earnings prospects, as indicated by a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 14.5%, with one estimate moving higher and no negative revisions [12] - RRGB holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does provide a directional guide for price movement [14]

Company Overview - Vir Biotechnology, Inc. (VIR) shares increased by 11.9% to close at $5.93, with trading volume significantly higher than usual, contrasting with a 2.2% loss over the past four weeks [1][2] Pipeline and Development - The rise in stock price is linked to positive investor sentiment regarding tobevibart, Vir Biotechnology's late-stage pipeline candidate, which is in a phase III ECLIPSE 1 study for chronic hepatitis delta (CHD) treatment [2] - The company is preparing to start a phase III ECLIPSE 2 study to evaluate the efficacy and safety of switching to tobevibart and elebsiran for CHD patients not achieving viral suppression with bulevirtide [2] Financial Expectations - The upcoming quarterly report is expected to show a loss of $0.74 per share, reflecting a year-over-year increase of 27.5%, while revenues are projected at $7.05 million, up 128.8% from the previous year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Vir Biotechnology operates within the Zacks Medical - Biomedical and Genetics industry, which includes other companies like Opus Genetics, Inc. (IRD), that also has a Zacks Rank of 2 (Buy) [4][5]

Company Overview - TopBuild shares increased by 6.1% to close at $378.8, supported by strong trading volume, and have gained 15.3% over the past four weeks [1][2] - The company announced an $810 million cash acquisition of Progressive Roofing, which is expected to enhance its position in the commercial roofing segment [2] Financial Performance - TopBuild is projected to report quarterly earnings of $5.10 per share, reflecting a year-over-year decline of 5.9%, with expected revenues of $1.29 billion, down 5.5% from the previous year [3] - The consensus EPS estimate for TopBuild has remained unchanged over the last 30 days, indicating stability in earnings expectations [4] Industry Context - TopBuild is part of the Zacks Building Products - Miscellaneous industry, which includes other companies like Janus International Group, Inc. [5] - Janus International Group's consensus EPS estimate has also remained unchanged at $0.15, representing a year-over-year decline of 28.6% [6]

Core Insights - Analysts project State Street Corporation (STT) will report quarterly earnings of $2.36 per share, a 9.8% increase year over year, with revenues expected to reach $3.37 billion, up 5.7% from the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has been revised 4.5% higher in the last 30 days, indicating a collective reevaluation by analysts [2] - Revisions to earnings projections are critical for predicting investor behavior and are strongly linked to short-term stock price performance [3] Key Metrics Projections - Analysts expect the 'Basel III Advanced Approaches - Tier 1 Leverage Ratio' to reach 5.4%, up from 5.3% in the same quarter last year [5] - The 'Average balance - Total interest-earning assets' is projected at $291.11 billion, compared to $261.74 billion a year ago [5] - The 'Basel III Standardized Approach - Tier 1 capital ratio' is expected to be 13.6%, an increase from 13.3% year over year [6] - 'Assets under Management (AUM)' is forecasted to be $4800.97 billion, up from $4415.00 billion in the same quarter last year [6] - The 'Basel III Standardized Approach - Total capital ratio' is estimated at 14.7%, down from 15.0% a year ago [7] - 'Assets under Custody and/or Administration (AUC/A)' is projected at $41922.09 billion, compared to $44312.00 billion last year [7] Revenue Projections - 'Net Interest Income' is estimated at $734.82 million, slightly down from $735.00 million in the same quarter last year [8] - 'Total fee revenue' is projected to reach $2.64 billion, up from $2.46 billion a year ago [8] - 'Net Interest Income - fully taxable-equivalent basis' is expected to be $733.49 million, compared to $736.00 million last year [9] - 'Software and processing fees' are estimated at $231.30 million, up from $214.00 million in the same quarter last year [9] - 'Other fee revenue' is projected at $58.70 million, compared to $48.00 million a year ago [10] - 'Management fees' are expected to reach $558.82 million, up from $511.00 million last year [10] Stock Performance - Shares of State Street have increased by 12.4% in the past month, outperforming the Zacks S&P 500 composite, which rose by 4.4% [10]

Core Viewpoint - Eaton's stock has shown a strong performance recently, returning +10.5% over the past month, outperforming the S&P 500's +4.4% and the Zacks Manufacturing - Electronics industry's +10.1% [1] Earnings Estimate Revisions - The consensus earnings estimate for Eaton is $2.92 per share for the current quarter, reflecting a year-over-year increase of +7% [4] - The consensus estimate for the current fiscal year is $12.02, indicating a year-over-year change of +11.3% [4] - For the next fiscal year, the consensus estimate is $13.62, representing a +13.3% change from the previous year [5] Revenue Growth Projections - Eaton's consensus sales estimate for the current quarter is $6.93 billion, showing a year-over-year increase of +9.1% [10] - The revenue estimates for the current and next fiscal years are $27.36 billion and $29.55 billion, indicating changes of +10% and +8%, respectively [10] Last Reported Results and Surprise History - In the last reported quarter, Eaton generated revenues of $6.38 billion, a year-over-year increase of +7.3% [11] - The EPS for the same period was $2.72, compared to $2.4 a year ago, with a revenue surprise of +1.78% and an EPS surprise of +0.74% [11] - Eaton has beaten consensus EPS estimates in each of the trailing four quarters, while topping revenue estimates just once [12] Valuation - Eaton has a Zacks Rank of 3 (Hold), indicating it may perform in line with the broader market in the near term [6][17] - The Zacks Value Style Score for Eaton is graded D, suggesting it is trading at a premium compared to its peers [16]

Core Viewpoint - GE Vernova (GEV) has been trending as a stock of interest, with a notable performance compared to the broader market and its industry [1][2]. Earnings Estimates - For the current quarter, GE Vernova is projected to report earnings of $1.58 per share, reflecting a year-over-year increase of +122.5%. The consensus estimate has seen a slight decrease of -2.7% over the last 30 days [5]. - The consensus earnings estimate for the current fiscal year stands at $7.21, indicating a +29.2% change from the previous year, with a minor increase of +0.8% in the last month [5]. - For the next fiscal year, the earnings estimate is $11.34, suggesting a +57.2% increase compared to the prior year, with a recent adjustment of +0.5% [6]. Revenue Growth Forecast - The consensus sales estimate for the current quarter is $8.82 billion, which represents a year-over-year growth of +7.5%. For the current and next fiscal years, the sales estimates are $37.21 billion and $40.94 billion, indicating growth rates of +6.5% and +10%, respectively [11]. Last Reported Results - In the last reported quarter, GE Vernova achieved revenues of $8.03 billion, marking a +10.6% increase year-over-year. The EPS was $0.91, a significant improvement from -$0.41 a year ago. The revenue exceeded the Zacks Consensus Estimate of $7.54 billion by +6.46%, and the EPS surpassed estimates by +102.22% [12]. Valuation - GE Vernova is graded C on the Zacks Value Style Score, suggesting that it is trading at par with its peers. This assessment is based on various valuation metrics, including price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) [17].